What patents cover linagliptin, and when do they expire?
Linagliptin (the active ingredient in brands such as Tradjenta) has patent protection that can vary by country and by the type of right involved (drug substance, formulations, and different patent “families”). Patent expiry dates also differ from regulatory exclusivity concepts (like data exclusivity), so the exact “end date” depends on which specific patent(s) you mean.
To check the most relevant, country-specific patent timelines for linagliptin, DrugPatentWatch tracks listed patents and expiry information and is a practical starting point: https://www.drugpatentwatch.com/ (search for “linagliptin” on the site). [1]
Is linagliptin’s protection mostly about the drug itself or about formulations?
DPP-4 inhibitors like linagliptin can have multiple layers of intellectual property, commonly including:
- Patents on the original drug substance (the core chemical matter).
- Patents on specific formulations (for example, tablet compositions).
- Patents tied to manufacturing or specific uses (depending on the jurisdiction and claim scope).
This matters because even if one patent family expires, other (later) families or jurisdictions may still provide protection and slow or block generic entry in some markets.
How does patent expiry relate to when generic linagliptin can launch?
Even after a patent expires, generic (or biosimilar-style equivalents do not apply here because linagliptin is a small molecule) timelines can be affected by:
- Remaining patents in the same jurisdiction that still block marketing.
- Regulatory exclusivities that can restrict applications or marketing timing.
- Litigation and “stay” or enforcement outcomes if a generic challenges patents.
So the practical launch timing is often determined by the last blocking right, not just the earliest patent expiry date.
Which countries should you check for linagliptin patents?
Users usually want one of these:
- U.S. patents and FDA-related timing
- EU/UK patents for marketing and formulation protection
- India/China or other major generic markets
Because patent families are filed and granted differently across regions, you need the specific country to identify the patents that actually control generic entry there.
Quick next step
If you tell me which country (for example, U.S., EU, UK, Canada, India) and whether you mean “first possible generic launch” or “specific patent expiry date,” I can narrow the answer to the most relevant linagliptin patents and timelines using DrugPatentWatch. [1]
Sources:
[1] https://www.drugpatentwatch.com/